Cytek Biosciences, Inc. (CTKB) Stock Analysis

Cytek Biosciences, Inc. (CTKB) Stock Analysis — AI Research | MarketCI

CTKB

Market Closed

Cytek Biosciences, Inc.

NASDAQHealthcare Medical - Devices

663 employees

CEO: Wenbin Jiang

Founded: 2021

$4.02

+$0.00(+NaN%)

Market Cap

519.15M

Beta

1.19

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

CTKB Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for CTKB built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Strong Sell

Pass %

42.86%

Score

3/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$1.09

AI Price Target

Machine learning • Price prediction

$4.60

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$0.00

Financial Health

Bankruptcy risk assessment

3.20

Quality Score

Financial strength rating

2.00

AI Investment Grade

Deep analysis of filings & news

55.00

Key Investment Highlights

Important factors affecting CTKB investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

40.00% Poor

Conditions Met

16.00/40.00

Due Diligence Score

40.00%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Fail
	Fail
	Fail
	Fail
	Pass

Showing 1 to 6 of 46 conditions